This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM5)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04126200
Recruitment Status : Recruiting
First Posted : October 15, 2019
Last Update Posted : February 26, 2024
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
B-cell maturation antigen (BCMA) is a target present on tumor cells in participants with multiple myeloma. Belantamab mafodotin (GSK2857916); is an antibody-drug conjugate (ADC) containing humanized anti-BCMA monoclonal antibody (mAb). This is a phase I/II, randomized, open-label, platform study designed to evaluate the effects of belantamab mafodotin in combination with other anti-cancer drugs in participants with relapsed/refractory multiple myeloma. The Platform design incorporates a single master protocol, where multiple treatment combinations, as sub-studies, will be evaluated simultaneously.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: Belantamab mafodotin Drug: GSK3174998 Drug: Feladilimab Drug: Nirogacestat Drug: Dostarlimab Drug: Isatuximab Drug: Lenalidomide Drug: Dexamethasone Drug: Pomalidomide Phase 1 Phase 2

Expanded Access : An investigational treatment associated with this study is available outside the clinical trial.   More info ...

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 464 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: There will be a dose exploration (DE) phase which will evaluate the safety and tolerability profile of belantamab mafodotin when administered in combination with other anti-cancer treatments. A recommended Phase 2 dose (RP2D) for each combination treatment will be identified based on the safety and preliminary efficacy in DE. This will be followed by a cohort expansion (CE) phase which will evaluate the clinical activity of the combination treatment in comparison to belantamab mafodotin monotherapy in additional participants.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5
Actual Study Start Date : October 7, 2019
Estimated Primary Completion Date : February 24, 2026
Estimated Study Completion Date : February 12, 2029

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma
Drug Information available for: Belantamab

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Belantamab mafodotin+GSK3174998 dose exploration (Sub-study 1) Drug: Belantamab mafodotin
Belantamab mafodotin will be administered.

Drug: GSK3174998
GSK3174998 will be administered.
Experimental: Belantamab mafodotin+feladilimab dose exploration (Sub-study 2) Drug: Belantamab mafodotin
Belantamab mafodotin will be administered.

Drug: Feladilimab
feladilimab will be administered.
Experimental: Belantamab mafodotin+nirogacestat dose exploration(Sub-study 3) Drug: Belantamab mafodotin
Belantamab mafodotin will be administered.

Drug: Nirogacestat
Nirogacestat will be administered.
Experimental: Belantamab mafodotin+dostarlimab dose exploration(Sub-study 4) Drug: Belantamab mafodotin
Belantamab mafodotin will be administered.

Drug: Dostarlimab
Dostarlimab will be administered.
Experimental: Belantamab mafodotin+isatuximab dose exploration (Sub-study 5) Drug: Belantamab mafodotin
Belantamab mafodotin will be administered.

Drug: Isatuximab
Isatuximab will be administered.
Experimental: Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone dose exploration (Sub-study 6) Drug: Belantamab mafodotin
Belantamab mafodotin will be administered.

Drug: Nirogacestat
Nirogacestat will be administered.

Drug: Lenalidomide
Lenalidomide will be administered.

Drug: Dexamethasone
Dexamethasone will be administered.
Experimental: Belantamab mafodotin+ nirogacestat+ pomalidomide + dexamethasone dose exploration (Sub-study 7) Drug: Belantamab mafodotin
Belantamab mafodotin will be administered.

Drug: Nirogacestat
Nirogacestat will be administered.

Drug: Dexamethasone
Dexamethasone will be administered.

Drug: Pomalidomide
Pomalidomide will be administered.
Experimental: Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone dose exploration (Sub-study 8)
This cohort will enroll Northeast Asian participants.
 Drug: Belantamab mafodotin
Belantamab mafodotin will be administered.

Drug: Nirogacestat
Nirogacestat will be administered.

Drug: Lenalidomide
Lenalidomide will be administered.

Drug: Dexamethasone
Dexamethasone will be administered.
Active Comparator: Belantamab mafodotin monotherapy cohort expansion Drug: Belantamab mafodotin
Belantamab mafodotin will be administered.
Experimental: Belantamab mafodotin+GSK3174998 cohort expansion (Sub-study 1) Drug: Belantamab mafodotin
Belantamab mafodotin will be administered.

Drug: GSK3174998
GSK3174998 will be administered.
Experimental: Belantamab mafodotin+ feladilimab cohort expansion (Sub-study 2) Drug: Belantamab mafodotin
Belantamab mafodotin will be administered.

Drug: Feladilimab
feladilimab will be administered.
Experimental: Belantamab mafodotin+ nirogacestat cohort expansion (Sub-study 3) Drug: Belantamab mafodotin
Belantamab mafodotin will be administered.

Drug: Nirogacestat
Nirogacestat will be administered.
Experimental: Belantamab mafodotin+ dostarlimab cohort expansion (Sub-study 4) Drug: Belantamab mafodotin
Belantamab mafodotin will be administered.

Drug: Dostarlimab
Dostarlimab will be administered.
Experimental: Belantamab mafodotin+ isatuximab cohort expansion (Sub-study 5) Drug: Belantamab mafodotin
Belantamab mafodotin will be administered.

Drug: Isatuximab
Isatuximab will be administered.
Experimental: Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone cohort expansion (Sub-study 6) Drug: Belantamab mafodotin
Belantamab mafodotin will be administered.

Drug: Nirogacestat
Nirogacestat will be administered.

Drug: Lenalidomide
Lenalidomide will be administered.

Drug: Dexamethasone
Dexamethasone will be administered.
Experimental: Belantamab mafodotin+ nirogacestat+ pomalidomide + dexamethasone cohort expansion (Sub-study 7) Drug: Belantamab mafodotin
Belantamab mafodotin will be administered.

Drug: Nirogacestat
Nirogacestat will be administered.

Drug: Dexamethasone
Dexamethasone will be administered.

Drug: Pomalidomide
Pomalidomide will be administered.
Experimental: Belantamab mafodotin+ nirogacestat+ lenalidomide+ dexamethasone cohort expansion (Sub-study 8)
This cohort will enroll Northeast Asian participants.
 Drug: Belantamab mafodotin
Belantamab mafodotin will be administered.

Drug: Nirogacestat
Nirogacestat will be administered.

Drug: Lenalidomide
Lenalidomide will be administered.

Drug: Dexamethasone
Dexamethasone will be administered.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. DE Phase: Number of participants achieving dose limiting toxicities (DLT) [ Time Frame: Up to 12 months ]
    An event is considered to be a DLT if the event occurs within the first 28 days of treatment and meets protocol defined DLT criteria.

  2. DE Phase: Number of participants with adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: Up to 12 months ]
    AEs and SAEs will be collected.

  3. DE Phase: Number of participants with clinically significant changes in hematology, clinical chemistry and urinalysis lab parameters [ Time Frame: Up to 12 months ]
    Blood and urine samples will be collected to evaluate hematology, clinical chemistry and urinalysis lab parameters.

  4. CE Phase: Number of participants achieving Overall Response Rate (ORR) [ Time Frame: Up to 36 months ]
    ORR is defined as the percentage of participants with a Partial response (PR) or better, according to the International Myeloma Working Group (IMWG) Response Criteria.


Secondary Outcome Measures :
  1. DE Phase: Number of participants achieving ORR [ Time Frame: Up to 12 months ]
    ORR is defined as the percentage of participants with PR or better, according to the IMWG Response Criteria.

  2. CE Phase: Number of participants achieving Clinical Benefit Rate (CBR) [ Time Frame: Up to 36 months ]
    CBR is defined as the percentage of participants with a minimal response (MR) or better, according to IMWG response criteria.

  3. DE Phase: Number of participants achieving Partial Response (PR) [ Time Frame: Up to 12 months ]
    Number of participants with PR according to IMWG criteria will be analyzed.

  4. CE Phase: Number of participants achieving PR [ Time Frame: Up to 36 months ]
    Number of participants with PR according to IMWG criteria will be analyzed.

  5. DE Phase: Number of participants achieving Very Good Partial Response (VGPR) [ Time Frame: Up to 12 months ]
    Number of participants with VGPR according to IMWG criteria will be analyzed.

  6. CE Phase: Number of participants achieving VGPR [ Time Frame: Up to 36 months ]
    Number of participants with VGPR according to IMWG criteria will be analyzed.

  7. DE Phase: Number of participants achieving Complete Response (CR) [ Time Frame: Up to 12 months ]
    Participants with CR according to IMWG criteria will be analyzed.

  8. CE Phase: Number of participants achieving CR [ Time Frame: Up to 36 months ]
    Participants with CR according to IMWG criteria will be analyzed.

  9. DE Phase: Number of participants achieving stringent Complete Response (sCR) [ Time Frame: Up to 12 months ]
    Participants with sCR according to IMWG criteria will be analyzed.

  10. CE Phase: Number of participants achieving sCR [ Time Frame: Up to 36 months ]
    Participants with sCR according to IMWG criteria will be analyzed.

  11. DE Phase: Belantamab mafodotin concentrations when administered in combination with anti-cancer treatments [ Time Frame: Up to 12 months ]
    Blood samples will be collected for concentrations of belantamab mafodotin.

  12. CE Phase: Belantamab mafodotin concentrations when administered in combination with anti-cancer treatments [ Time Frame: Up to 36 months ]
    Blood samples will be collected for concentrations of belantamab mafodotin.

  13. DE Phase: GSK3174998 concentration when administered in combination with belantamab mafodotin [ Time Frame: Up to 12 months ]
    Blood samples will be collected for concentrations of GSK3174998.

  14. CE Phase: GSK3174998 concentration when administered in combination with belantamab mafodotin [ Time Frame: Up to 36 months ]
    Blood samples will be collected for concentrations of GSK3174998.

  15. DE Phase: Feladilimab concentration when administered in combination with belantamab mafodotin [ Time Frame: Up to 12 months ]
    Blood samples will be collected for concentrations of feladilimab.

  16. CE Phase: Feladilimab concentration when administered in combination with belantamab mafodotin [ Time Frame: Up to 36 months ]
    Blood samples will be collected for concentrations of feladilimab.

  17. DE Phase: Nirogacestat concentration when administered in combination with belantamab mafodotin [ Time Frame: Up to 12 months ]
    Blood samples will be collected for concentrations of nirogacestat.

  18. CE Phase: Nirogacestat concentration when administered in combination with belantamab mafodotin [ Time Frame: Up to 36 months ]
    Blood samples will be collected for concentrations of nirogacestat.

  19. DE Phase: Dostarlimab concentration when administered in combination with belantamab mafodotin [ Time Frame: Up to 12 months ]
    Blood samples will be collected for concentrations of dostarlimab.

  20. CE Phase: Dostarlimab concentration when administered in combination with belantamab mafodotin [ Time Frame: Up to 36 months ]
    Blood samples will be collected for concentrations of dostarlimab.

  21. DE Phase: Isatuximab concentration when administered in combination with belantamab mafodotin [ Time Frame: Up to 12 months ]
    Blood samples will be collected for concentrations of isatuximab.

  22. CE Phase: Isatuximab concentration when administered in combination with belantamab mafodotin [ Time Frame: Up to 36 months ]
    Blood samples will be collected for concentrations of isatuximab.

  23. DE Phase: Concentration of anti-drug antibodies (ADAs) against belantamab mafodotin when administered in combination with anti-cancer treatments [ Time Frame: Up to 12 months ]
    Blood samples for concentrations for ADAs will be collected.

  24. CE Phase: Concentration of ADAs against belantamab mafodotin when administered in combination with anti-cancer treatments [ Time Frame: Up to 36 months ]
    Blood samples for concentrations for ADAs will be collected.

  25. DE Phase: Concentration of ADAs against GSK3174998 when administered in combination with belantamab mafodotin [ Time Frame: Up to 12 months ]
    Blood samples for concentrations for ADAs will be collected.

  26. CE Phase: Concentration of ADAs against GSK3174998 when administered in combination with belantamab mafodotin [ Time Frame: Up to 36 months ]
    Blood samples for concentrations for ADAs will be collected.

  27. DE Phase: Concentration of ADAs against feladilimab when administered in combination with belantamab mafodotin [ Time Frame: Up to 12 months ]
    Blood samples for concentrations for ADAs will be collected.

  28. CE Phase: Concentration of ADAs against feladilimab when administered in combination with belantamab mafodotin [ Time Frame: Up to 36 months ]
    Blood samples for concentrations for ADAs will be collected.

  29. DE Phase: Concentration of ADAs against dostarlimab when administered in combination with belantamab mafodotin [ Time Frame: Up to 12 months ]
    Blood samples for concentrations for ADAs will be collected.

  30. CE Phase: Concentration of ADAs against dostarlimab when administered in combination with belantamab mafodotin [ Time Frame: Up to 36 months ]
    Blood samples for concentrations for ADAs will be collected.

  31. DE Phase: Concentration of ADAs against isatuximab when administered in combination with belantamab mafodotin [ Time Frame: Up to 12 months ]
    Blood samples for concentrations for ADAs will be collected.

  32. CE Phase: Concentration of ADAs against isatuximab when administered in combination with belantamab mafodotin [ Time Frame: Up to 36 months ]
    Blood samples for concentrations for ADAs will be collected.

  33. DE Phase: Number of participants with adverse events of special interest (AESI) for belantamab mafodotin [ Time Frame: Up to 12 months ]
    AESIs will be collected.

  34. CE Phase: Number of participants with AESI for belantamab mafodotin [ Time Frame: Up to 36 months ]
    AESIs will be collected.

  35. DE Phase: Number of participants with AESI for GSK3174998 [ Time Frame: Up to 12 months ]
    AESIs will be collected.

  36. CE Phase: Number of participants with AESI for GSK3174998 [ Time Frame: Up to 36 months ]
    AESIs will be collected.

  37. DE Phase: Number of participants with AESI for Feladilimab [ Time Frame: Up to 12 months ]
    AESIs will be collected.

  38. CE Phase: Number of participants with AESI for Feladilimab [ Time Frame: Up to 36 months ]
    AESIs will be collected.

  39. DE Phase: Number of participants with AESI for Nirogacestat [ Time Frame: Up to 12 months ]
    AESIs will be collected.

  40. CE Phase: Number of participants with AESI for Nirogacestat [ Time Frame: Up to 36 months ]
    AESIs will be collected.

  41. DE Phase: Number of participants with AESI for Dostarlimab [ Time Frame: Up to 12 months ]
    AESIs will be collected.

  42. CE Phase: Number of participants with AESI for Dostarlimab [ Time Frame: Up to 36 months ]
    AESIs will be collected.

  43. DE Phase: Number of participants with AESI for Isatuximab [ Time Frame: Up to 12 months ]
    AESIs will be collected.

  44. CE Phase: Number of participants with AESI for Isatuximab [ Time Frame: Up to 36 months ]
    AESIs will be collected.

  45. DE Phase: Number of participants with abnormal ocular findings on ophthalmic examination [ Time Frame: Up to 12 months ]
    Ophthalmic examination will assess abnormal findings.

  46. CE Phase: Number of participants with abnormal ocular findings on ophthalmic examination [ Time Frame: Up to 36 months ]
    Ophthalmic examination will assess abnormal findings.

  47. CE Phase: Number of participants achieving Progression-free survival (PFS) [ Time Frame: Up to 36 months ]
    PFS is defined as the time from randomization until the earliest date of confirmed progressive disease (PD) per IMWG, or death due to any cause.

  48. CE Phase: Duration of response (DoR) [ Time Frame: Up to 36 months ]
    DoR is defined as the time from first documented evidence or PR or better until progressive disease per IMWG or death due to progressive disease among participants who achieve confirmed partial response or better.

  49. CE Phase: Time to response (TTR) [ Time Frame: Up to 36 months ]
    TTR is defined as the time between the date of randomization and the first documented evidence of response (PR or better), among participants who achieve a response (confirmed PR or better).

  50. CE Phase: Number of participants achieving Overall survival (OS) [ Time Frame: Up to 36 months ]
    OS is defined as the time from randomization until death due to any cause.

  51. CE Phase: Number of participants with AEs and SAEs [ Time Frame: Up to 36 months ]
    AEs and SAEs will be collected.

  52. CE Phase: Number of participants with AEs leading to discontinuation [ Time Frame: Up to 36 months ]
    Number of participants with AEs leading to discontinuation will be evaluated.

  53. CE Phase: Number of participants with dose reduction or delay [ Time Frame: Up to 36 months ]
    Number of participants with dose reduction or delay will be evaluated.

  54. CE Phase: Number of participants with clinically significant changes in hematology, clinical chemistry and urinalysis lab parameters [ Time Frame: Up to 36 months ]
    Blood and urine samples will be collected to evaluate hematology, clinical chemistry and urinalysis lab parameters.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participant must be 18 years of age inclusive or older, at the time of signing the informed consent.
  • Participants must have histologically or cytologically confirmed diagnosis of Multiple Myeloma (MM), as defined by the IMWG.
  • Participants having at least 3 prior lines of prior anti-myeloma treatments including an immunomodulating agent (IMID) a proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody.
  • Participants with a history of autologous stem cell transplant are eligible for study participation when, transplant was >100 days prior to study enrolment and with no active infection(s).
  • Participants with Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, unless ECOG less than equal to (<=)2 is due solely to skeletal complications and/or skeletal pain due to MM.
  • Participants with measurable disease defined as at least one of the following: Serum M-protein greater than equal to (>=)0.5 gram per deciliter (>=5 gram per liter) or Urine M-protein >=200 milligrams (mg) per 24 hours or Serum free light chain (FLC) assay: Involved FLC level >=10 mg per deciliter (>=100 mg per Liter) and an abnormal serum FLC ratio (<0.26 or >1.65).
  • Participants who have tested positive for Hepatitis B core antibody (HBcAb) can be enrolled if the following criteria are met: Serology result HBcAb+, Hepatitis B surface antigen (HBsAg)-; HBV deoxyribonucleic acid (DNA) undetectable during screening.
  • Participants who are currently receiving physiological doses oral steroids (<10 mg/day), inhaled steroids or ophthalmalogical steroids.

Inclusion Criteria Specific to Sub-study 6,7, and 8:

  • Participants with contraception requirements specific to Sub-study 6, 7, and 8 respectively.
  • Participants with platelets value for Adequate Organ System Function is ≥75 × 10^9/L.

Inclusion Criteria Specific to Sub-study 8:

- In Japan, participants should reside in Japan and be Japanese as defined by having all biological Japanese grandparents. Similarly, in China, subjects should reside in China and be Chinese as defined by having all biological Chinese grandparents.

Exclusion Criteria:

  • Participants with current corneal epithelial disease except mild punctate keratopathy.
  • Participants with evidence of cardiovascular risk.
  • Participants with known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to belantamab mafodotin or any of the components of the study treatment. History of severe hypersensitivity to other mAb.
  • Participants with active infection requiring antibiotic, antiviral, or antifungal treatment.
  • Participants with other monoclonal antibodies within 30 days or systemic anti-myeloma therapy within <14 days.
  • Participants with prior radiotherapy within 2 weeks of start of study therapy.
  • Participants with prior allogeneic transplant are prohibited.
  • Participants who have received prior Chimeric Antigen T cell therapy (CAR-T) therapy with lymphodepletion with chemotherapy within 3 months of screening.
  • Participants with any major surgery (other than bone-stabilizing surgery) within the last 30 days.
  • Participants with prior treatment with an investigational agent within 14 days or 5 half-lives of receiving the first dose of study drugs, whichever is shorter.
  • Participants with >=grade 3 toxicity considered related to prior check-point inhibitors and that led to treatment discontinuation.
  • Participants who have received transfusion of blood products within 2 weeks before the first dose of study drug.
  • Participants must not receive live attenuated vaccines within 30 days prior to first dose of study treatment or whilst receiving belantamab mafodotin +- partner agent in any sub-study arm of the platform trial and for at least 70 days following last study treatment.
  • Participants with presence of active renal condition (infection, requirement for dialysis or any other condition that could affect participant's safety). Participants with isolated proteinuria resulting from MM.
  • Participants with known human immunodeficiency virus (HIV) infection, unless the participant can meet all criteria: a) established anti-retroviral therapy for at least 4 weeks and HIV viral load<400 copies/milliliter (mL) b) cluster of differentiation 4 plus (CD4+) T-cell (CD4+) counts >= 350 cells/microliter (µL) c) No history of Acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within the last 12 months in which case the participant would be eligible for CE Phase only.

For participants receiving nirogacestat, HIV drugs that are strong Cytochrome P450 3A4 (CYP3A4) inhibitors are prohibited. HIV drugs that are moderate CYP3A4 inhibitors, while permitted, should be co-administered with caution and must be accompanied by nirogacestat dose modifications.

Additional Exclusion Criteria for Sub-study 1 and 2:

  • Participants with autoimmune disease (current or history) or syndrome that required systemic treatment within the past 2 years.
  • Exclusion for a recent (within the past 6 months) history of symptomatic pericarditis.

Additional Exclusion Criteria for Sub-study 3, 6, 7, and 8:

  • Participants with uncontrolled small and/or large intestinal disease.
  • Participants with uncontrolled skin disease.
  • Participants with any condition causing hypophosphatemia, hypokalemia or hypomagnesemia which is refractory to electrolyte replacement.
  • Participants with previous administration of a gamma secretase inhibitor.
  • Participants with concomitant administration of a strong CYP3A4 inhibitor or inducer.

Additional Exclusion Criteria for Sub-study 4:

  • Participant has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs).
  • Participants who have received prior therapy with an anti-programmed death-1 (anti-PD-1), anti-PD-1-ligand-1 (anti-PD-L1), or anti-PD-1 ligand-2 (anti-PD-L2) agent.
  • Participant has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment. Use of inhaled steroids, local injection of steroids, and steroid eye drops are allowed.

Additional Exclusion Criteria for Sub-study 5:

  • Participants with Severe hypersensitivity to Isatuximab-irfc or to any of its excipients.
  • Participants with prior treatment with other anti-CD38 monoclonal antibody within 6 months of the first dose of study drug treatment.
  • Participants with known intolerance or hypersensitivity to infused proteins products, sucrose, histidine, and polysorbate 80.

Additional Exclusion Criteria for Sub-study 6, 7, and 8:

  • Participants with active or history of venous thromboembolism within the past 3 months.
  • Participants with evidence of active mucosal or internal bleeding.
  • Participants with contraindications to or are unwilling to undergo protocol-required anti-thrombotic prophylaxis or unable to tolerate antithrombolitic prophalaxis.

Additional Exclusion Criteria for Sub-study 6 and 8:

- Participants who discontinued prior treatment with lenalidomide due to intolerable adverse events.

Additional Exclusion Criteria for Sub-study 7:

- Participants who discontinued prior treatment with pomalidomide due to intolerable adverse events.

Additional Exclusion Criteria for Sub-study 8:

  • Pregnant or lactating female or female who are interrupting lactation.
  • Previously diagnosed with interstitial lung disease or current complication of interstitial lung disease.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04126200


Contacts
Layout table for location contacts
Contact: US GSK Clinical Trials Call Center 877-379-3718 GSKClinicalSupportHD@gsk.com
Contact: EU GSK Clinical Trials Call Center +44 (0) 20 89904466 GSKClinicalSupportHD@gsk.com

Locations
Show Show 59 study locations
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline
  Study Documents (Full-Text)

Documents provided by GlaxoSmithKline:
Study Protocol  [PDF] February 12, 2024

More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT04126200    
Other Study ID Numbers: 208887
First Posted: October 15, 2019    Key Record Dates
Last Update Posted: February 26, 2024
Last Verified: February 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: IPD for this study will be made available via the Clinical Study Data Request site.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access Criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
URL: http://clinicalstudydatarequest.com

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by GlaxoSmithKline:
Belantamab mafodotin
GSK2857916
GSK3174998
Feladilimab
Nirogacestat
Dostarlimab
 Isatuximab
Lenalidomide
Dexamethasone
Pomalidomide
Platform study
Relapsed/Refractory Multiple Myeloma
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone
 Lenalidomide
Pomalidomide
Dostarlimab
Nirogacestat
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents